British COVID-19 drug Sotrovimab approved: effective against Omicron
- Brief Intermittent Exercise Reduces Heart Disease and Death Risk
- Personalized Lung Tumor Chips Assess PD-1 Therapy Response
- Study Shows Prior Infection Offers Strong Immunity to Original COVID-19 Strain
- Chinese Food Products Dominate Korean Tables Amid Safety Concerns
- Early Detection of Hypopharyngeal Cancer Possible with Saliva Diagnosis
- EB Virus Could Be Infected by Kiss: A Hidden Threat Linked to Cancer
British COVID-19 drug Sotrovimab approved: effective against Omicron
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
British COVID-19 drug Sotrovimab approved: effective against Omicron.
Recently, the new coronavirus mutant strain Omicron reported in South Africa has attracted global attention, and the WHO has assessed its overall global risk as “very high”, which means that it may spread widely in the world.
According to foreign media reports, a study published on the preprint server “BioRxiv” showed that a COVID-19 monoclonal antibody drug called “Sotrovimab” is effective against Omicron.
The report pointed out that “Sotrovimab” was developed by the British GlaxoSmithKline (GSK) and the American biotechnology company Vir Biotechnology (VIR).
However, the research has not yet passed peer review.
The research was conducted on a pseudovirus of all variants of the new coronavirus, including key mutations carried by the Omicron strain.
The results showed that the “Sotrovimab” monoclonal antibody was still active against Omicron strain.
Vir CEO Dr. George Scangos (George Scangos) said in a statement that “Sotrovimab” is specially designed.
When the design points out, it takes into account the possible mutation of the virus, and the antibody targets the spike protein. The part where mutations are unlikely to occur.
It is worth mentioning that due to the high infectivity and ability of the Omicron strain to evade vaccine protection, many vaccine companies are developing new vaccines against it.
American vaccine company Moderna CEO Stephane Bancel (Stephane Bancel) has stated that the existing vaccines will be far less effective in dealing with the Omicron strain, and there will be a substantial decline.
At present, the British Medicines and Medical Products Regulatory Agency has approved “Sotrovimab” for the treatment of COVID-19. In addition, the United States, Japan and other countries have also approved “Sotrovimab” for the treatment of COVID-19s.
British COVID-19 drug Sotrovimab approved: effective against Omicron.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.